The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported data from the IgA nephropathy and chronic kidney disease (CKD) associated with Type I diabetes cohorts of the open-label, U.S. Phase II PHOENIX trial of bardoxolone methyl to treat rare...
bluebird bio Inc. (NASDAQ:BLUE), Reata Pharmaceuticals Inc. (NASDAQ:RETA) and Catalent Inc. (NYSE:CTLT) each priced follow-ons late July 24, together raising more than $1 billion. bluebird raised $550 million through the sale of 3.4 million shares...
Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported Phase II data showing that chronic kidney disease (CKD) patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR) four weeks after discontinuing treatment. In 25...
Reata Pharmaceuticals Inc. (NASDAQ:RETA) added $30.15 (65%) to $76.55 on Monday after reporting Phase II data showing that chronic kidney disease patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR)...
The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported additional data from 30 patients with chronic kidney disease (CKD) caused by Alport syndrome in the open-label Phase II portion of the Phase II/III CARDINAL trial showing that once-daily oral...
Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported data from 30 patients with chronic kidney disease (CKD) caused by Alport syndrome in the open-label Phase II portion of the Phase II/III CARDINAL trial showing that once-daily oral bardoxolone...
Reata Pharmaceuticals Inc. (NASDAQ:RETA) gained $4.37 (14%) to $35.47 on Monday after saying it will move ahead to the Phase III portion of the Phase II/III CARDINAL study of bardoxolone methyl ( RTA 402 )...
Reata began a U.S. Phase II/III trial to evaluate bardoxolone in 210 patients with the rare form of chronic kidney disease (CKD). The open-label Phase II portion will enroll up to 30 patients. Adult patients...